In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 25 of 371

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]	Technology appraisal guidance	TBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]	Technology appraisal guidance	5 November 2025
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	TBC
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354	Technology appraisal guidance	TBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]	Technology appraisal guidance	TBC
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	TBC
Aggressive behaviour in people receiving NHS or social care: prevention and management	NICE guideline	TBC
Alcohol Use Disorders (update)	NICE guideline	TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]	Technology appraisal guidance	TBC
ALXN1840 for treating Wilson disease TS ID 9950	Technology appraisal guidance	TBC
Alzheimer's disease (early) - gantenerumab [ID6142]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	23 October 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]	Technology appraisal guidance	20 August 2025
Amyotrophic lateral sclerosis - SAR443820 [ID6386]	Technology appraisal guidance	TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence software to help detect and characterise colorectal polyps	Diagnostics guidance	5 March 2026
Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures : Early Value Assessment	Health technology evaluation	10 October 2025
Artificial intelligence-based technologies to aid lung function measurement for the diagnosis of suspected lung conditions: Early Value Assessment	Health technology evaluation	2 April 2026
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]	Technology appraisal guidance	TBC

Results per page

10
25
50
All